Conrad, M. et al. Cell death in cancer. Cell 189, 2322–2356 (2026).
Mao, C., Jiang, D., Koong, A. C. & Gan, B. Exploiting metabolic cell death for cancer therapy. Nat. Rev. Cancer 26, 27–45 (2026).
Amaria, R. N. et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 611, 155–160 (2022).
Huang, Q. et al. The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. Cell 185, 4049–4066 (2022).
Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24–34 (2022).
Sharma, P. et al. Immune checkpoint therapy—current perspectives and future directions. Cell 186, 1652–1669 (2023).
Gulhati, P. et al. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nat. Cancer 4, 62–80 (2023).
Abril-Rodriguez, G. et al. PAK4 inhibition improves PD-1 blockade immunotherapy. Nat. Cancer 1, 46–58 (2020).
Wang, Q. et al. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature 579, 421–426 (2020).
Zhang, Z. et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature 579, 415–420 (2020).
Zhang, T. et al. ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis. Nature 606, 594–602 (2022).
He, S. & Wang, X. RIP kinases as modulators of inflammation and immunity. Nat. Immunol. 19, 912–922 (2018).
Li, L. et al. Burst release of encapsulated annexin A5 in tumours boosts cytotoxic T-cell responses by blocking the phagocytosis of apoptotic cells. Nat. Biomed. Eng. 4, 1102–1116 (2020).
Meier, P., Legrand, A. J., Adam, D. & Silke, J. Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity. Nat. Rev. Cancer 24, 299–315 (2024).
Yuan, J. & Ofengeim, D. A guide to cell death pathways. Nat. Rev. Mol. Cell Biol. 25, 379–395 (2024).
Broz, P., Pelegrín, P. & Shao, F. The gasdermins, a protein family executing cell death and inflammation. Nat. Rev. Immunol. 20, 143–157 (2019).
Gao, W., Wang, X., Zhou, Y., Wang, X. & Yu, Y. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Signal Transduct. Target. Ther. 7, 196 (2022).
Su, W. et al. A dual-responsive STAT3 inhibitor nanoprodrug combined with oncolytic virus elicits synergistic antitumor immune responses by igniting pyroptosis. Adv. Mater. 35, e2209379 (2023).
Wang, Z. et al. Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy. Nat. Nanotechnol. 16, 1130–1140 (2021).
Chen, B. et al. In situ-generated vaccine-like pyroptosome for personalized cancer immunotherapy. Nat. Mater. 25, 856–867 (2026).
Vandenabeele, P., Bultynck, G. & Savvides, S. N. Pore-forming proteins as drivers of membrane permeabilization in cell death pathways. Nat. Rev. Mol. Cell Biol. 24, 312–333 (2023).
Wang, Y. et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature 547, 99–103 (2017).
Devant, P. & Kagan, J. C. Molecular mechanisms of gasdermin D pore-forming activity. Nat. Immunol. 24, 1064–1075 (2023).
Kesavardhana, S., Malireddi, R. K. S. & Kanneganti, T.-D. Caspases in cell death, inflammation, and pyroptosis. Annu. Rev. Immunol. 38, 567–595 (2020).
Man, S. M. & Kanneganti, T.-D. Converging roles of caspases in inflammasome activation, cell death and innate immunity. Nat. Rev. Immunol. 16, 7–21 (2015).
Bertheloot, D., Latz, E. & Franklin, B. S. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. Cell. Mol. Immunol. 18, 1106–1121 (2021).
Peltzer, N. & Walczak, H. Cell death and inflammation—a vital but dangerous liaison. Trends Immunol. 40, 387–402 (2019).
Newton, K., Strasser, A., Kayagaki, N. & Dixit, V. M. Cell death. Cell 187, 235–256 (2024).
Liu, M. et al. A transistor-like pH-sensitive nanodetergent for selective cancer therapy. Nat. Nanotechnol. 17, 541–551 (2022).
Shen, W. et al. Antineoplastic drug-free anticancer strategy enabled by host-defense-peptides-mimicking synthetic polypeptides. Adv. Mater. 32, e2001108 (2020).
Xiong, M. et al. Selective killing of Helicobacter pylori with pH-responsive helix-coil conformation transitionable antimicrobial polypeptides. Proc. Natl Acad. Sci. USA 114, 12675–12680 (2017).
Shao, N. et al. Heterochiral β-peptide polymers combating multidrug-resistant cancers effectively without inducing drug resistance. J. Am. Chem. Soc. 144, 7283–7294 (2022).
Liu, L. et al. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat. Nanotechnol. 4, 457–463 (2009).
Wang, J. et al. pH-ultrasensitive membranolytic polyesters with alternating sequence of ionizable and hydrophobic groups for selective oncolytic therapy. J. Am. Chem. Soc. 147, 1008–1016 (2025).
Forveille, S. et al. The oncolytic peptide LTX-315 triggers necrotic cell death. Cell Cycle 14, 3506–3512 (2015).
Yamazaki, T. et al. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade. Cell Death Differ. 23, 1004–1015 (2016).
Xiong, M. et al. Bacteria-assisted activation of antimicrobial polypeptides by a random-coil to helix transition. Angew. Chem. Int. Ed. 56, 10826–10829 (2017).
Qi, G. B., Zhang, D., Liu, F. H., Qiao, Z. Y. & Wang, H. An “on–site transformation” strategy for treatment of bacterial infection. Adv. Mater. 29, 1703461 (2017).
Zhang, W. et al. The relationship between in vivo toxicity and responsive pH in transistor-like pH-sensitive nanodetergents. Small Methods 9, 2401263 (2025).
Boedtkjer, E. & Pedersen, S. F. The acidic tumor microenvironment as a driver of cancer. Annu. Rev. Physiol. 82, 103–126 (2020).
Du, J.-Z., Li, H.-J. & Wang, J. Tumor-acidity-cleavable maleic acid amide (TACMAA): a powerful tool for designing smart nanoparticles to overcome delivery barriers in cancer nanomedicine. Acc. Chem. Res. 51, 2848–2856 (2018).
Settembre, C. & Perera, R. M. Lysosomes as coordinators of cellular catabolism, metabolic signalling and organ physiology. Nat. Rev. Mol. Cell Biol. 25, 223–245 (2024).
Aits, S. et al. Sensitive detection of lysosomal membrane permeabilization by lysosomal galectin puncta assay. Autophagy 11, 1408–1424 (2015).
Skowyra, M. L., Schlesinger, P. H., Naismith, T. V. & Hanson, P. I. Triggered recruitment of ESCRT machinery promotes endolysosomal repair. Science 360, eaar5078 (2018).
Wang, F., Gómez-Sintes, R. & Boya, P. Lysosomal membrane permeabilization and cell death. Traffic 19, 918–931 (2018).
Liu, H. et al. From oncolytic peptides to oncolytic polymers: a new paradigm for oncotherapy. Bioact. Mater. 31, 206–230 (2024).
Galluzzi, L., Guilbaud, E., Schmidt, D., Kroemer, G. & Marincola, F. M. Targeting immunogenic cell stress and death for cancer therapy. Nat. Rev. Drug Discov. 23, 445–460 (2024).
Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A. & Sahay, G. Strategies for non-viral vectors targeting organs beyond the liver. Nat. Nanotechnol. 19, 428–447 (2024).
Wang, Q. et al. Commensal-driven serotonin production modulates in vivo delivery of synthetic and viral vectors. Science 391, eadu7686 (2026).
Duong, E. et al. Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Immunity 55, 308–323 (2022).
Peng, F. et al. Regulated cell death (RCD) in cancer: key pathways and targeted therapies. Signal Transduct. Target. Ther. 7, 286 (2022).
Zhang, J. et al. Tandem-controlled lysosomal assembly of nanofibres induces pyroptosis for cancer immunotherapy. Nat. Nanotechnol. 20, 563–574 (2025).
Gemingnuer, A., Yin, R., Liu, Y., Tian, Y. & Meng, X. Lysosome-dependent cell death: disease implications and potential therapeutic targets. Mol. Biol. Rep. 52, 881 (2025).
Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487–500 (2022).
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97–111 (2016).
Xiong, M. et al. Helical antimicrobial polypeptides with radial amphiphilicity. Proc. Natl Acad. Sci. USA 112, 13155–13160 (2015).
Lu, H. et al. Ionic polypeptides with unusual helical stability. Nat. Commun. 2, 206 (2011).
Zhang, Y. et al. SAGE1: a potential target antigen for lung cancer T-cell immunotherapy. Mol. Cancer Ther. 20, 2302–2313 (2021).
Rapoport, A. P. et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21, 914–921 (2015).
Tomayko, M. M. & Reynolds, C. P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 24, 148–154 (1989).
